◄ back to all posts

ORGS: Orgenesis, Inc. Stock

Written by | Jul, 6, 2018

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 68.81
Enterprise Value ($M) 69.10
Book Value ($M) 20.76
Book Value / Share 1.30
Price / Book 3.49
NCAV ($M) -15.20
NCAV / Share -0.95
Price / NCAV -4.59

Profitability (mra)
Return on Invested Capital (ROIC) -0.67
Return on Assets (ROA) -0.48
Return on Equity (ROE) -1.35

Liquidity (mrq)
Quick Ratio 1.01
Current Ratio 1.10

Balance Sheet (mrq) ($M)
Current Assets 23.93
Assets 84.77
Liabilities 39.14
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 18.66
Operating Income -14.65
Net Income -19.10
Earnings Per Share Diluted -1.43
Earnings Per Share Basic -1.43

Cash Flow Statement (mra) ($M)
Cash From Operations -15.68
Cash from Investing -6.27
Cash from Financing -6.27

Source:
Fintel.io

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
2019-01-08 13D/A Bultot Hugues 4.20 -11.98

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

Source:
Fintel.io

Date Insider Trades Code Shares Value

Source:
Fintel.io

File Date Form SEC Filings
2019-05-08 10-Q ORGS / Orgenesis, Inc. 10-Q Quarterly Report FORM 10-Q
2019-02-13 10-K ORGS / Orgenesis, Inc. FORM 10-K (Annual Report)
2018-10-12 10-Q ORGS / Orgenesis, Inc. FORM 10-Q (Quarterly Report)
2018-07-17 10-Q ORGS / Orgenesis, Inc. FORM 10-Q (Quarterly Report)

Source:
Fintel.io

Similar Companies
OPHT – Ophthotech Corp OPK – Opko Health, Inc.
OREX – Orexigen Therapeutics, Inc. ORMP – Oramed Pharmaceuticals, Inc.
OSIR – Osiris Therapeutics, Inc.


Financial data and stock pages provided for FREE by
Fintel.io




2018/07/06
◄ back to all posts
401 K